Science Corp. reports 36-month data for the PRIMA implant

The company's October note

Science Corporation's release, dated October 5, 2026, says 36-month data from the pivotal PRIMAvera trial were presented in a late-breaking session at the EURETINA meeting by Mahi Muqit of Moorfields Eye Hospital. The trial implanted 38 patients at 17 sites in five European countries. The company says 27 patients were evaluable for safety at 36 months. The implant is 2 millimeters by 2 millimeters by 30 micrometers. It sits in the atrophied retina and works with glasses that send near-infrared light. A bill of materials for a board is a different hardware questiona bill of materials.

What the meeting write-ups count

Eyewire's October 14 account says three-year results were presented at the American Academy of Ophthalmology, with 18 patients evaluated at 36 months, acuity with the device improving from about 20/460 to about 20/120, and 78 percent gaining at least three lines. Science's note names EURETINA and a safety count of 27. Two meetings can carry related data. This page will not force 18 and 27 to be the same denominator. The hardware desk is Asked directly, What visual result does Eyewire report? Among 18 patients at 36 months, mean acuity with the device moved from about 20/460 to about 20/120, and 78 percent gained at least three lines. Those figures are Eyewire's account of the meeting, not a number this page recomputed.Hardware.

What the magazine adds

MIT Technology Review's October 16 article is the wire's account. It describes glasses, a near-infrared projector, and an implant whose pixels both stimulate remaining retinal cells and draw power from the light, so there is no battery in the eye. It says the system was approved in Europe in July and is awaiting FDA clearance, and that after training more than 80 percent of recipients in its telling could read and use a phone. Frank Brodie is quoted as the medical director. The training claim and the 80 percent figure stay inside that article. The paper isFutureweb.

Where it can be offered

The company's news post says PRIMA is commercially available in Europe and the United Kingdom and pending FDA approval in the United States. The patient page is stricter about the rest of the world: CE marked in the EU, registered for supply in the UK, and not approved or for sale in any other country. Pending is not approved. A U.S. reader does not have a commercial product in these pages. The mobile desk, for a phone rather than an implant, isMobile.

Who the company says it is for

Science says age-related macular degeneration affects a very large population, and that this generation of PRIMA is for a subset with advanced geographic atrophy and severe central vision loss, typically people over 60. It says the device was originally developed by Daniel Palanker at Stanford and that Science manufactures the current version and is designing a later one with a wider field. The current brief is about the 36-month report, not the unshipped successor. The privacy desk isPrivacy.

What this page will not describe

How a surgeon places the chip is not in this brief. The size, the light, and the regulatory status are. Adverse-event detail beyond the company's statement that a safety set was evaluable at 36 months stays in the clinical record, not in a paraphrase. The security desk is Asked directly, What is the implant, in the company's words? A subretinal photovoltaic implant, 2 millimeters by 2 millimeters by 30 micrometers, used with glasses that project near-infrared light. A zoom feature magnifies letters. Science says it is meant to stand in for lost light-sensitive cells.Security.

How to hold the numbers

Enrollment of 38 is the company's. The 27-patient safety line is the company's. The 18-patient acuity line is Eyewire's account of a poster or paper at a U.S. meeting. The more-than-80-percent daily-task line is MIT Technology Review's. A reader who wants one percentage for every patient in the trial will not find it on this page, because the sources are not counting the same set. The software desk is Asked directly, Where can a patient get it? Science says it is commercially available in Europe and the United Kingdom and pending FDA approval in the United States. The patient page says it is CE marked in the European Union, registered in the UK, and not approved for sale in any other country.Software.

The original paper, unnamed here

Science says the earlier PRIMA results were published in the New England Journal of Medicine. This brief does not restate that paper. The news is the 36-month presentation and the commercial status in Europe and the UK. Energy is Asked directly, How many patients does Science Corporation say were implanted? 38 patients at 17 sites in five European countries. The company says 27 were evaluable for safety at 36 months. Eyewire's account of an Academy of Ophthalmology presentation talks about 18 patients at 36 months. This page will not merge those counts.Energy.

The line to keep

A photovoltaic retinal implant with three-year data presented in October, sold in Europe and the UK, not approved in the United States. Acuity figures stay attached to the outlet that printed them. The short answer this page will stand on is this: That 36-month follow-up from the PRIMAvera trial was presented at a European retina meeting. The company says 38 patients were implanted in five countries. It says the device is sold in Europe and the UK and is still awaiting U.S. approval.